Form 4: Camp4 Therapeutics Director Granted 9,000 Stock Options

James P. Boylan, a Director at Camp4 Therapeutics Corp, was granted 9,000 stock options with an exercise price of $1.56, vesting over one year or by the next annual meeting.

Summary

• James P. Boylan, a Director of Camp4 Therapeutics Corp (CAMP), was granted 9,000 stock options.
• The options have an exercise price of $1.56 per share.
• The grant date for these options was June 25, 2025.
• The options are exercisable immediately upon grant and expire on June 24, 2035.
• The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.

Sentiment

Score: 6

Explanation: The filing reports a routine stock option grant to a director, which is a neutral to slightly positive event as it aligns director incentives with shareholder interests, but does not indicate significant operational or financial news.

Positives

• The grant of stock options to Director James P. Boylan aligns his interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the director to the company's board.

Negatives

• No specific negative implications are directly discernible from this routine insider transaction filing.

Risks

• This Form 4 filing does not disclose specific risks to the company's operations or financial health.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continued service from Director James P. Boylan to the Camp4 Therapeutics board of directors for at least one year or until the next annual meeting of stockholders.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This practice aims to align the interests of leadership with those of shareholders by providing an incentive tied to the company's stock performance. Such grants are standard mechanisms for attracting and retaining experienced board members in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The grant of 9,000 stock options to a director is a typical form of equity compensation.
• While specific comparable companies or projects are not detailed in this filing, similar option grants are routinely observed across small to mid-cap biotechnology firms as part of their non-employee director compensation plans.
• The exercise price of $1.56 would typically be the fair market value of the stock on the grant date, which is standard practice.

Related Party Transactions

• The stock option grant to James P. Boylan, a director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The director's continued service to the board is required for the options to vest fully.

Key Dates

Keywords

SEC Form 4, Camp4 Therapeutics, CAMP, Stock Option Grant, Director Compensation, Insider Transaction, Beneficial Ownership, Equity Compensation, James P. Boylan